Last reviewed · How we verify
Lead Candidate
At a glance
| Generic name | Lead Candidate |
|---|---|
| Also known as | [18F]ABBV-965i, [18F]ABBV-964i |
| Sponsor | Invicro |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- headache
- vomiting
- anxiety
- localized edema
- nausea
- depression
- nasal congestion
- parasthesia
- psychiatric disorders, other - tics
- scalp pain
- Injection site pain
- akathisia
Key clinical trials
- Strong Evidence: Digitally Delivered Exercise in Older Adults (NA)
- Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound (PHASE4)
- First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain (EARLY_PHASE1)
- Responsive Deep Brain Stimulator for Essential Tremor (NA)
- Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI) (PHASE2)
- Stereotypic Behaviors and Feeding Difficulties in Adults With Developmental Disabilities (NA)
- Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females (PHASE3)
- A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |